| 摘要: |
| [摘要] 目的：观察阿奇霉素联合金振口服液治疗儿童支原体肺炎的有效性及安全性，为临床合理应用抗菌药物提供参考。方法：将2016年11月至2017年3月入许昌市中心医院治疗的支原体肺炎患儿280例作为研究对象，随机数字表法分为观察组和对照组各140例。观察组患儿应用阿奇霉素联合金振口服液治疗，对照组患儿单用阿奇霉素治疗。记录两组患儿退热时间、咳嗽消失时间、肺部啰音消失时间、住院时间及药品不良反应发生情况。结果：观察组总有效率为89.3%，高于对照组的77.9%，差异有统计学意义（P<0.05）；观察组退热时间、咳嗽消失时间、肺部锣音消失时间和住院时间分别为（4.14±1.31）d、（5.82±2.25）d、（6.14±2.19）d和（8.52±2.28）d，明显低于对照组的（5.28±1.62）d、（7.82±2.48）d、（8.53±2.46）d和（11.37±2.74）d，差异均有统计学意义（P<0.05）；不良反应发生率两组比较差异无统计学意义（P>0.05）。结论：阿奇霉素联合金振口服液治疗儿童支原体肺炎临床症状消失更快，疗效优于阿奇霉素单一治疗，值得临床推广应用。 |
| 关键词: 阿奇霉素 金振口服液 支原体肺炎 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2019.04.012 |
|
| 基金项目: |
|
| Azithromycin Combined with Jinzhen Oral Liquid in the Treatment of Children with Mycoplasma Pneumonia Pneumonia |
| Xu Bingxin1,2, Zhao Yan1,2, Qu Xin1, Kong Rui1 |
| (1.Xuchang Central Hospital, Henan Xuchang 461000, China; 2.Xuchang Key Laboratory of Molecular Medicine, Henan Xuchang 461000, China) |
| Abstract: |
| [Abstract] Objective: To observe the efficacy and safety of azithromycin combined with Jinzhen oral liquid in the treatment of children with Mycoplasma pneumonia pneumonia (MPP), so as to provide reference for the clinical rational application of antibiotics. Methods: A total of 280 children with MPP admitted into Xuchang Central Hospital from Nov. 2016 to Mar. 2017 were extracted to be divided into the observation group and the control group via the random number table, with 140 cases in each group. Children in the observation group were treated with azithromycin combined with Jinzhen oral liquid, while the control group received azithromycin alone. The relief time of fever, disappearance time of cough and lung rales, stay of length and adverse drug reactions of two groups were recorded. Results: The total effective rate of the observation group was 89.3%, higher than 77.9% of the control group, the difference was statistically significant (P<0.05). The relief time of fever, disappearance time of cough and lung rales, and stay of length in observation group were respectively (4.14±1.31) d, (5.82±2.25) d, (6.14±2.19) d and (8.52±2.28) d, significantly lower than those of the control group (5.28±1.62) d, (7.82±2.48) d, (8.53±2.46) d and (11.37±2.74) d, the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse drug reactions between two groups (P>0.05). Conclusion: Azithromycin combined with Jinzhen oral liquid in the treatment of children with MPP is more conducive to improving the clinical symptoms, with better efficacy compared with the treatment of azithromycin alone, it is worthy of clinical application. |
| Key words: azithromycin Jinzhen oral liquid Mycoplasma pneumonia pneumonia |
